%0 Journal Article
%T Recent Developments in Methicillin-Resistant Staphylococcus aureus (MRSA) Treatment: A Review.
%A Nandhini P
%A Kumar P
%A Mickymaray S
%A Alothaim AS
%A Somasundaram J
%A Rajan M
%J Antibiotics (Basel)
%V 11
%N 5
%D Apr 2022 29
%M 35625250
%F 5.222
%R 10.3390/antibiotics11050606
%X Staphylococcus aureus (S. aureus) is a Gram-positive bacterium that may cause life-threatening diseases and some minor infections in living organisms. However, it shows notorious effects when it becomes resistant to antibiotics. Strain variants of bacteria, viruses, fungi, and parasites that have become resistant to existing multiple antimicrobials are termed as superbugs. Methicillin is a semisynthetic antibiotic drug that was used to inhibit staphylococci pathogens. The S. aureus resistant to methicillin is known as methicillin-resistant Staphylococcus aureus (MRSA), which became a superbug due to its defiant activity against the antibiotics and medications most commonly used to treat major and minor infections. Successful MRSA infection management involves rapid identification of the infected site, culture and susceptibility tests, evidence-based treatment, and appropriate preventive protocols. This review describes the clinical management of MRSA pathogenesis, recent developments in rapid diagnosis, and antimicrobial treatment choices for MRSA.